Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) announces that the FDA has granted emergency use authorization (EUA) for a rapid antigen test capable of detecting SARS-CoV-2, influenza A, and influenza B in a single test. The BD Veritor™ Plus System test will be available this summer, enabling healthcare providers to distinguish between these viral infections quickly. The test delivers results in about 15 minutes, streamlining the diagnostic process during the flu season. BD currently has over 70,000 active testing systems across multiple healthcare settings.
BD (Becton, Dickinson and Company) has partnered with ImageMover to launch a mobile app that enhances the reporting of SARS-CoV-2 antigen testing results from the BD Veritor™ Plus System. This app aims to simplify data collection at everyday settings like schools and businesses, addressing the challenges of managing test subject demographics and reporting. Available immediately, the ImageMover app provides secure, automated reporting to health authorities, streamlining the process for organizations lacking sophisticated IT infrastructure. The partnership supports BD's innovation in COVID-19 testing solutions.
BD (Becton, Dickinson and Company) has acquired GSL Solutions, Inc., a company specializing in smart medication devices that enhance the security and efficiency of medication storage and compliance. This acquisition aims to bolster BD's medication management capabilities in retail pharmacies and outpatient settings. BD sees this as a strategic move to address growing market demands for automated tracking of medications. GSL's technology includes RFID-based systems that improve operational efficiency and reduce patient wait times. The transaction is expected to be immaterial financially.
BD (Becton, Dickinson and Company) (NYSE: BDX) announced a collaboration with Scanwell Health to develop an at-home rapid test for SARS-CoV-2. This new test will utilize a BD antigen test paired with Scanwell's mobile app, offering step-by-step instructions for sample collection. Users can analyze results using their device's camera, with plans for automated reporting to health agencies. The initiative aims to enhance COVID-19 testing accessibility. BD has played a significant role in the COVID-19 response, providing a range of diagnostic solutions.
BD (Becton, Dickinson and Company) announced its participation in two upcoming virtual investor conferences. The company will present at the Leerink Virtual 10th Annual Global Healthcare Conference on February 24, 2021, at 1:00 p.m. ET, and the Raymond James Virtual 42nd Annual Institutional Investors Conference on March 2, 2021, at 8:20 a.m. ET. Interested investors can access live webcasts and replays on the BD corporate website.
BD (Becton, Dickinson and Company) has received Emergency Use Authorization (EUA) from the FDA for a new molecular diagnostic test that detects both SARS-CoV-2 and Influenza A+B within 2-3 hours. This test is designed to identify variants from the U.K. and South Africa, with 99.9% match to genetic sequences of these variants. The BD SARS-CoV-2/Flu assay operates on the BD MAX™ System, a platform that can analyze hundreds of samples daily. The product is now available in the U.S. and Europe as part of BD's ongoing response to COVID-19.
BD (Becton, Dickinson and Company) reported first fiscal quarter revenues of $5.315 billion, a 25.8% increase year-over-year, driven by $867 million from COVID-19 diagnostics. Diluted EPS rose to $3.35, up 285.1% from the previous year. The BD Medical segment saw revenues of $2.261 billion, while BD Life Sciences grew to $1.979 billion, reflecting significant COVID-19 contributions. BD expects fiscal 2021 revenue growth of 12% to 14% and adjusted EPS of $12.75 to $12.85, indicating robust financial momentum.
BD (Becton, Dickinson and Company) announced positive outcomes from the CLEAN3 trial, demonstrating that its vascular care solution significantly reduces peripheral intravenous catheter (PIVC) failures, showing rates of 34.8% versus 47.5% in the control group. The trial observed enhanced performance regarding antiseptics, with catheter colonization at 0.9% compared to 16.9%. Conducted at Poitiers University Hospital, France, the study involved around 1,000 patients, highlighting the benefits of BD’s integrated solution for improving patient safety and reducing hospital costs.
On January 26, 2021, BD (Becton, Dickinson and Company) announced that Tom Polen, current CEO, will also become chairman of the board effective April 28, 2021. He succeeds Vincent A. Forlenza, retiring after leading BD through significant transformations. Under Polen's leadership, BD expanded its role during the COVID-19 pandemic by enhancing diagnostic testing and manufacturing essential medical supplies. Polen, with over 20 years at BD, aims to drive the BD 2025 strategy focused on growth, simplification, and empowerment to improve global healthcare delivery.
The Board of Directors of BD (Becton, Dickinson and Company) has announced a quarterly dividend of $0.83 per share, payable on March 31, 2021, to shareholders on record as of March 10, 2021. This marks an annual dividend rate of $3.32 per share. BD is a leading global medical technology company focused on enhancing health care delivery and improving medical diagnostics through innovative solutions, impacting health outcomes globally.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
